Abstract

Objective: The study aims to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients. Method: We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG, n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG, n=40, treated solely with targeted therapy). Results: The OG group reported 4 cases of Complete Response (CR), 24 cases of Partial Response (PR), 10 cases of Stable Disease (SD), and 2 cases of Progressive Disease (PD). The Overall Response Rate (ORR) was 70.00% (28/40), and the Disease Control Rate (DCR) was 95.00% (38/40). In contrast, the CG group exhibited 3 cases of CR, 20 cases of PR, 12 cases of SD, and 5 cases of PD. The ORR was 57.50% (23/40), and the DCR was 87.50% (35/40). The ORR and DCR in the OG group were significantly higher than those in the CG group. After 6 weeks of treatment, the levels of SCC, CEA, and CA125 in the OG group were significantly lower than those in the CG group; The CD4+ levels in the OG group were significantly higher and the CD8+ levels significantly lower than those in the CG group. A 24-month follow-up showed that the survival rate of the OG group was 47.50% (19/40), which was significantly higher than that of the CG group at 27.50% (11/40). Conclusion: CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.

Keywords: Lung Cancer, Radiofrequency Ablation, Targeted Therapy, Clinical Efficacy, Immune Response, Safety, Survival Time